AstraZeneca Halts Major Lung-Cancer Trial After Experimental Immunotherapy Falls Short

AstraZeneca has discontinued its Phase III eVOLVE-Lung02 trial on 17 August 2026 after an independent data monitoring committee concluded that the experimental immunotherapy volrustomig, when combined with chemotherapy, was unlikely to deliver the hoped-for survival benefit in a key group of patients with metastatic non-small-cell lung cancer. The global study was testing volrustomig, a bispecific antibody designed to target the immune checkpoints PD-1 and CTLA-4, against the established first-line combination of pembrolizumab and chemotherapy, with particular attention to patients whose tumours expressed low levels of the PD-L1 biomarker. The committee’s assessment found that the experimental regimen was unlikely to meet either of its primary endpoints—improving progression-free survival, which measures how long patients live without their cancer worsening, or overall survival—in patients whose tumours were PD-L1-negative, prompting the company to stop the trial rather than continue exposing participants to an approach unlikely to outperform the comparator. Importantly, AstraZeneca said the decision was driven by lack of expected efficacy rather than a newly identified safety problem: the safety profile of volrustomig plus chemotherapy remained consistent with what was already known about the individual treatments, and no new safety signals were detected. The setback is significant because volrustomig had been one of AstraZeneca’s advanced immuno-oncology candidates and, as recently as July 2026, eVOLVE-Lung02 remained listed in the company’s Phase III lung-cancer development programme. While the result does not mean that PD-1/CTLA-4 bispecific antibodies have failed as a class, it highlights one of the realities of cancer-drug development: promising biological mechanisms and encouraging earlier-stage findings do not always translate into longer survival when tested against modern standard treatments in large, late-stage trials. For patients and oncologists, the outcome also reinforces why randomised Phase III studies remain essential before new immunotherapies can replace established care, allowing ineffective strategies to be identified while researchers redirect attention towards treatments and patient groups where meaningful clinical benefit may still be achievable.